Moxifloxacin punctal plug - Ocular Therapeutix

Drug Profile

Moxifloxacin punctal plug - Ocular Therapeutix

Alternative Names: Moxifloxacin sustained-release - Ocular Therapeutix; OTX-MP

Latest Information Update: 22 May 2015

Price : $50

At a glance

  • Originator Ocular Therapeutix
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Conjunctivitis

Most Recent Events

  • 20 May 2015 Pharmacokinetics and adverse events data from a phase I trial in Conjunctivitis (Bacterial conjunctivitis in post-cataract surgery patients) released by Ocular Therapeutix before May 2015 (Ocular Therapeutix From S-1; May 2015)
  • 20 May 2015 Ocular Therapeutix plans a phase II trial in Conjunctivitis (Bacterial conjunctivitis) in USA (Ocular Therapeutix From S-1; May 2015)
  • 01 Dec 2010 Ocular Therapeutix completes a phase I trial in Conjunctivitis (Bacterial conjunctivitis in post-cataract surgery patients) in Singapore (Ocular Therapeutix From S-1; May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top